Compare Crispr Therapeutics AG (CRSP) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Essex Property Trust, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Essex Property Trust, Inc. trades at $271.57 (market cap $17.26B). The key difference: Essex Property Trust, Inc. is far larger — about 3.5× Crispr Therapeutics AG's market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Essex Property Trust, Inc. for 111 Days on average.
| CRSP | ESS | |
|---|---|---|
Market Cap | $4.88B | $17.26B |
Volume | 2,861,747 | 454,464 |
Sector | Health | Real Estate |
52-Week High | $74.92 | $298.33 |
52-Week Low | $44.34 | $239.61 |
Typical Hold Time | 77 Days | 111 Days |
Enterprise Value | $3.30B | $23.86B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
ESS trades at $268.58, up 0.2% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with revenue reaching $1.89 billion in 2025. Analyst consensus is a Buy with a $303.41 price target, though the stock faces headwinds from high valuation multiples and legal uncertainties recently resolved.
The outlook for ESS is cautiously optimistic, supported by strong operational efficiency and raised full-year guidance, but risks include elevated debt levels and sensitivity to real estate market cycles. Investment appeal hinges on execution of growth strategies amid economic fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
